Syngene International has announced the conclusion of its acquisition of a multi-modal biologics manufacturing facility, known as ‘Unit 3’, from Stelis Biopharma Ltd. The deal was finalized at a revised gross value of Rs 617 crores, adjusted from the initial value of Rs 702 crores. Revised Deal Terms Reflect Equipment Retention The reduction in the […]
Pharma manufacturing services company Syngene International has unveiled plans to acquire Unit 3 biologics manufacturing facility located in Bangalore, India from Stelis Biopharma Limited (SBL). The agreement will result in an additional 20,000 liters of installed biologics drug substance manufacturing capacity for Syngene, with the possibility of doubling this figure in the future. The facility […]
Strides Pharma Science said that its biologics arm Stelis Biopharma has secured an establishment inspection report (EIR) from the US Food and Drug Administration (FDA) pertaining to the commercialization of drug-device combination products at its Bengaluru facility. Stelis Biopharma is an Indian contract development and manufacturing organization (CDMO). Strides Pharma Science said that the abbreviated […]
Stelis Biopharma Limited, a biopharma and vaccines company and the biotech arm of Strides Pharma Science has appointed Mark W. Womack as its new chief executive officer (CEO). Mark W. Womack is also the designated managing director and will be inducted to the board of directors later depending on the required statutory clearances and processes. […]